Spero Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Spero Therapeutics

04/11/2022 11:28

* Spero Therapeutics Inc  SPRO.OQ   SPRO.O  is expected
to show a
rise in quarterly revenue when it reports  results on November 8
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 76.8% increase in revenue to $5.417 million from $3.06
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Spero Therapeutics
Inc is
for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Spero
Therapeutics Inc is $6​, above​ its last closing price of $1.88.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.92       -0.93      -0.87     Beat    6.1
 Mar. 31 2022  -0.86       -0.87      -1.01     Missed  -16.2
 Dec. 31 2021  -0.78       -0.75      -0.90     Missed  -20.4​
 Sep. 30 2021  -0.64       -0.66      -0.70     Missed  -5.5
 ​​Jun.        -0.74       -0.75      -0.63     Beat    16.1
 30 2021                                                
 Mar. 31 2021  -0.64       -0.64      -0.66     Missed  -2.3​
 Dec. 31 2020  -0.65       -0.74      -0.68     Beat    8.5
 Sep. 30 2020  -0.84       -0.87      -0.86     Beat    1.3
 This summary was machine generated November 4 at 11:28 GMT.  All
figures in US dollars  unless otherwise stated